Toripalimab Set For ASCO Buzz With New Nasopharyngeal Data
First-Line PFS Improvements
Junshi and Coherus's PD-1 was already gaining attention for a particularly difficult cancer type even before the meeting, but new data add to its luster ahead of a potential US approval.
